NASDAQ:IDYA - Nasdaq - US45166A1025 - Common Stock - Currency: USD
NASDAQ:IDYA (5/14/2025, 2:14:44 PM)
17.18
-0.27 (-1.55%)
The current stock price of IDYA is 17.18 USD. In the past month the price increased by 1.99%. In the past year, price decreased by -56.91%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.43 | 316.65B | ||
AMGN | AMGEN INC | 12.6 | 140.60B | ||
GILD | GILEAD SCIENCES INC | 12.8 | 123.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 107.87B | ||
REGN | REGENERON PHARMACEUTICALS | 12.86 | 61.52B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.43B | ||
ARGX | ARGENX SE - ADR | 90.86 | 32.56B | ||
ONC | BEIGENE LTD-ADR | 5.51 | 23.93B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.35B | ||
NTRA | NATERA INC | N/A | 20.59B | ||
BIIB | BIOGEN INC | 7.61 | 17.64B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.98B |
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
IDEAYA BIOSCIENCES INC
7000 Shoreline Ct, Suite 350
South San Francisco CALIFORNIA 94080 US
CEO: Yujiro Hata
Employees: 131
Phone: 16504436209
The current stock price of IDYA is 17.18 USD. The price decreased by -1.55% in the last trading session.
The exchange symbol of IDEAYA BIOSCIENCES INC is IDYA and it is listed on the Nasdaq exchange.
IDYA stock is listed on the Nasdaq exchange.
19 analysts have analysed IDYA and the average price target is 52.7 USD. This implies a price increase of 206.75% is expected in the next year compared to the current price of 17.18. Check the IDEAYA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IDEAYA BIOSCIENCES INC (IDYA) has a market capitalization of 1.50B USD. This makes IDYA a Small Cap stock.
IDEAYA BIOSCIENCES INC (IDYA) currently has 131 employees.
IDEAYA BIOSCIENCES INC (IDYA) has a support level at 17.42 and a resistance level at 18.35. Check the full technical report for a detailed analysis of IDYA support and resistance levels.
The Revenue of IDEAYA BIOSCIENCES INC (IDYA) is expected to grow by 228.54% in the next year. Check the estimates tab for more information on the IDYA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IDYA does not pay a dividend.
IDEAYA BIOSCIENCES INC (IDYA) will report earnings on 2025-08-04.
IDEAYA BIOSCIENCES INC (IDYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).
The outstanding short interest for IDEAYA BIOSCIENCES INC (IDYA) is 12.56% of its float. Check the ownership tab for more information on the IDYA short interest.
ChartMill assigns a technical rating of 1 / 10 to IDYA. When comparing the yearly performance of all stocks, IDYA is a bad performer in the overall market: 89.63% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to IDYA. While IDYA has a great health rating, there are worries on its profitability.
Over the last trailing twelve months IDYA reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -67.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.42% | ||
ROE | -25.91% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to IDYA. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 13.88% and a revenue growth 228.54% for IDYA